Zoledronic Acid is named as an intervention in 3 current clinical trials in our China and India registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is St. Louis University (1). The most-studied condition is Giant Cell Tumor of Bone.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
NCT03295981 · ClinicalTrials.gov ↗ · Giant Cell Tumor of Bone
|
Phase 3 | Recruiting | St. Louis University | India |
|
Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia
NCT07471516 · ClinicalTrials.gov ↗ · Congenital Dyserythropoietic Anemia (CDA)
|
Phase 1/2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer
NCT06876636 · ClinicalTrials.gov ↗ · Breast Cancer Metastatic
|
Not applicable | Active, closed | Xijing Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| St. Louis University | 1 |
| Xijing Hospital | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in India | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China and India registers name Zoledronic Acid as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in China and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
St. Louis University (1), Xijing Hospital (1) and Institute of Hematology & Blood Diseases Hospital, China (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Zoledronic Acid works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Zoledronic Acid works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Zoledronic Acid (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.